[
  {
    "ts": "2026-02-16T11:30:00+00:00",
    "headline": "Bio-Techne's Ella Platform Achieves CE-IVD Marking Expanding Access to Rapid, Cartridge‑Based Immunoassays for European Clinical Laboratories",
    "summary": "Bio-Techne Corporation (NASDAQ: TECH), a global provider of life science tools, reagents, and diagnostic products, today announced that the Ella benchtop immunoassay platform has received CE-IVD marking1 and is now available for sale in the European Union. This achievement brings Ella's hallmark ease of use, speed and reproducibility to clinical settings, helping laboratories streamline workflows and support timely decision-making.",
    "url": "https://finance.yahoo.com/news/bio-technes-ella-platform-achieves-113000228.html",
    "source": "PR Newswire",
    "provider": "yfinance",
    "raw": {
      "id": "7ab3aab5-cef8-3893-abf3-d3b16b00773d",
      "content": {
        "id": "7ab3aab5-cef8-3893-abf3-d3b16b00773d",
        "contentType": "STORY",
        "title": "Bio-Techne's Ella Platform Achieves CE-IVD Marking Expanding Access to Rapid, Cartridge‑Based Immunoassays for European Clinical Laboratories",
        "description": "",
        "summary": "Bio-Techne Corporation (NASDAQ: TECH), a global provider of life science tools, reagents, and diagnostic products, today announced that the Ella benchtop immunoassay platform has received CE-IVD marking1 and is now available for sale in the European Union. This achievement brings Ella's hallmark ease of use, speed and reproducibility to clinical settings, helping laboratories streamline workflows and support timely decision-making.",
        "pubDate": "2026-02-16T11:30:00Z",
        "displayTime": "2026-02-16T11:30:00Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/prnewswire.com/300dde1e8ea06c7a46071d80b01c0147",
          "originalWidth": 400,
          "originalHeight": 146,
          "caption": "BT Logo (PRNewsfoto/Bio-Techne Corporation)",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/ZyjXugroCeu5vlW6wYuCXA--~B/aD0xNDY7dz00MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/prnewswire.com/300dde1e8ea06c7a46071d80b01c0147.cf.webp",
              "width": 400,
              "height": 146,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/DPQWAvlZo522o8ucV.R5NA--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/prnewswire.com/300dde1e8ea06c7a46071d80b01c0147.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "PR Newswire",
          "url": "https://www.prnewswire.com/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/bio-technes-ella-platform-achieves-113000228.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/bio-technes-ella-platform-achieves-113000228.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "TECH"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  }
]